X4 Pharmaceuticals (XFOR) Cash from Investing Activities Growth (1y) (2018 - 2025)
X4 Pharmaceuticals (XFOR) Cash from Investing Activities Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 295.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 295.44% |
| Sep 30, 2025 | -79.98% |
| Jun 30, 2025 | -76.14% |
| Mar 31, 2025 | 41.04% |
| Dec 31, 2024 | -78.38% |
| Sep 30, 2024 | -208.88% |
| Jun 30, 2024 | 2,083.25% |
| Mar 31, 2024 | -59,033.33% |
| Dec 31, 2023 | -14,114.71% |
| Sep 30, 2023 | -57,200.00% |
| Jun 30, 2023 | -12,752.63% |
| Mar 31, 2023 | 59.09% |
| Dec 31, 2022 | -161.54% |
| Sep 30, 2022 | 55.00% |
| Jun 30, 2022 | 55.81% |
| Mar 31, 2022 | 95.56% |
| Dec 31, 2021 | 95.70% |
| Sep 30, 2021 | 95.97% |
| Jun 30, 2021 | -855.56% |
| Mar 31, 2021 | 10.63% |